PROFILPELAJAR.COM

Abexinostat
Names
	IUPAC name 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
	Other names PCI-24781; CRA-024781
Identifiers
CAS Number	783355-60-2 ; 783356-67-2 (HCl) ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:92223;
ChEMBL	ChEMBL2103863 ;
ChemSpider	9924562 ;
ECHA InfoCard	100.241.399
KEGG	D10060 ;
PubChem CID	11749858;
UNII	IYO470654U ; T1E6TM0SVG (HCl) ;
CompTox Dashboard (EPA)	DTXSID30229005 ;
	InChI InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) Key: MAUCONCHVWBMHK-UHFFFAOYSA-N ; InChI=1/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) Key: MAUCONCHVWBMHK-UHFFFAOYAM;
	SMILES O=C(NO)c3ccc(OCCNC(=O)c2oc1ccccc1c2CN(C)C)cc3;
Properties
Chemical formula	C21H23N3O5
Molar mass	397.431 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Abexinostat (INN,^[1] formerly PCI-24781) is an experimental drug candidate for cancer treatment.^[2] It was developed by Pharmacyclics and licensed to Xynomic. As of 2013^[update], it was in Phase II clinical trials for B-cell lymphoma.^[3]^{[needs update]} Pre-clinical study suggests the potential for treatment of different types of cancer as well.^[4]^[5]^[6]^[7]

Abexinostat exerts its effect as a pan-histone deacetylase inhibitor^[8]^[9] and inhibits RAD51, which is involved in repairing DNA double strand breaks.^[10]

Progress

Abexinostat has been granted a fast track designation by the FDA for the treatment of patients with relapsed or refractory follicular lymphoma in the fourth-line setting. This designation is significant as it aims to expedite the development and review of drugs intended to treat serious conditions and fill an unmet medical need.

Research

The FORERUNNER conducted a study, a potentially pivotal phase II trial of abexinostat monotherapy in patients with relapsed/refractory follicular lymphoma, in the United States and Europe.^[11] In the phase II study, abexinostat showed a modest overall response rate (ORR) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with a notably higher ORR observed in patients with follicular lymphoma. This study involved 100 patients treated with 80 mg of abexinostat twice daily for 14 days of a 21-day cycle. The ORR for follicular lymphoma specifically was 56%, indicating a significant impact on this lymphoma subtype. The study also reported grade ≥3 adverse events in a considerable number of patients, with thrombocytopenia, neutropenia, and anemia being the most frequently reported.^[11]

Safety and efficacy

Abexinostat has been characterized by its unique pharmacokinetic profile and oral dosing schedule, allowing for continuous exposure at concentrations required for efficient tumor cell killing. ^[12]